Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300 Million

FOSTER CITY, CA & SOUTH SAN FRANCISCO, CA, July 21, 2020 (Pitchbook) — Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it will invest $300 million to acquire a 49.9 percent equity interest in Tizona Therapeutics, Inc., a privately held company developing first-in-class cancer immunotherapies. Gilead will also receive an exclusive option to acquire the remainder of Tizona for up to an additional $1.25 billion, including an option exercise fee and potential future milestone payments. data.

Building Talent in the Covid-19 World

Why I Work In Healthcare